Exelixis, Inc. (NASDAQ:EXEL) Shares Sold by Milestone Asset Management LLC

Milestone Asset Management LLC reduced its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL) by 4.0% in the 2nd quarter, HoldingsChannel reports. The fund owned 25,946 shares of the biotechnology company’s stock after selling 1,082 shares during the quarter. Milestone Asset Management LLC’s holdings in Exelixis were worth $583,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the stock. Charles Schwab Investment Management Inc. boosted its holdings in Exelixis by 0.9% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 3,364,480 shares of the biotechnology company’s stock valued at $80,714,000 after purchasing an additional 28,840 shares in the last quarter. First Trust Advisors LP grew its position in Exelixis by 18.5% during the fourth quarter. First Trust Advisors LP now owns 3,152,755 shares of the biotechnology company’s stock worth $75,635,000 after buying an additional 492,613 shares during the period. Norges Bank purchased a new position in Exelixis in the fourth quarter valued at about $73,449,000. LSV Asset Management lifted its position in shares of Exelixis by 1,651.4% during the 1st quarter. LSV Asset Management now owns 2,774,707 shares of the biotechnology company’s stock valued at $65,844,000 after acquiring an additional 2,616,278 shares during the period. Finally, Los Angeles Capital Management LLC boosted its stake in shares of Exelixis by 948.3% during the 1st quarter. Los Angeles Capital Management LLC now owns 2,454,277 shares of the biotechnology company’s stock worth $58,240,000 after acquiring an additional 2,220,150 shares in the last quarter. Hedge funds and other institutional investors own 85.27% of the company’s stock.

Insiders Place Their Bets

In other news, CFO Christopher J. Senner sold 125,000 shares of Exelixis stock in a transaction that occurred on Friday, August 9th. The stock was sold at an average price of $27.19, for a total transaction of $3,398,750.00. Following the sale, the chief financial officer now owns 721,680 shares of the company’s stock, valued at approximately $19,622,479.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, CFO Christopher J. Senner sold 125,000 shares of the company’s stock in a transaction on Friday, August 9th. The stock was sold at an average price of $27.19, for a total transaction of $3,398,750.00. Following the transaction, the chief financial officer now owns 721,680 shares of the company’s stock, valued at $19,622,479.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Dana Aftab sold 95,000 shares of the company’s stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $25.00, for a total value of $2,375,000.00. Following the completion of the sale, the executive vice president now owns 520,990 shares of the company’s stock, valued at approximately $13,024,750. The disclosure for this sale can be found here. Insiders sold a total of 302,831 shares of company stock valued at $7,892,082 in the last quarter. Insiders own 2.85% of the company’s stock.

Exelixis Stock Up 0.9 %

Shares of EXEL traded up $0.24 during mid-day trading on Monday, hitting $26.59. 2,409,140 shares of the company’s stock were exchanged, compared to its average volume of 2,093,902. Exelixis, Inc. has a twelve month low of $18.64 and a twelve month high of $27.53. The firm has a fifty day moving average of $23.24 and a two-hundred day moving average of $22.51. The stock has a market cap of $8.06 billion, a price-to-earnings ratio of 41.55, a P/E/G ratio of 0.60 and a beta of 0.54.

Wall Street Analyst Weigh In

EXEL has been the subject of several research analyst reports. Stephens initiated coverage on Exelixis in a research note on Tuesday, May 14th. They issued an “equal weight” rating and a $23.00 price objective for the company. StockNews.com raised shares of Exelixis from a “buy” rating to a “strong-buy” rating in a research note on Saturday, July 13th. JMP Securities increased their price target on shares of Exelixis from $27.00 to $29.00 and gave the company a “market outperform” rating in a research report on Wednesday, August 7th. Truist Financial restated a “buy” rating and set a $33.00 price objective (up from $32.00) on shares of Exelixis in a research report on Thursday, August 8th. Finally, William Blair reiterated an “outperform” rating on shares of Exelixis in a research report on Wednesday, May 1st. Four research analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $27.43.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.